SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Munch-a-Biotech Today
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: LLCF who wrote (247)3/9/1999 12:03:00 PM
From: Thomas M.  Read Replies (1) of 3158
 
The global pharmaceutical market is growing 7.8% annually.

U.S. domestic pharmaceutical R&D spending will increase 17% this year.

One third of Merck's $15 billion in human health revenue in 1998 came from external sources (i.e. in-licensed drugs/compounds).

Of the 42 blockbuster drugs in 1997 (i.e. $500 million sales), 27% were in-licensed compounds.

Among the 10 largest pharmaceutical companies, in 1992 24% of gross revenues came from in-licensed compounds. By 1997 that number jumped to 30%. It is estimated to reach 45% by 2002.

(from article "Licensing for Profit" in the February 15 issue of Chemical & Engineering News)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News